Pyelonephritis - Pipeline Insight, 2024

This “Pyelonephritis- Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Pyelonephritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pyelonephritis: Understanding

Pyelonephritis: Overview

Pyelonephritis is a type of urinary tract infection where one or both kidneys become infected. They can be infected by bacteria or a virus. It can cause people to feel very sick and it requires treatment. There are approximately 250,000 cases of acute pyelonephritis each year, resulting in more than 100,000 hospitalizations. The most common etiologic cause is infection with Escherichia coli. The combination of the leukocyte esterase test and the nitrite test (with either test proving positive) has a sensitivity of 75 to 84 percent and a specificity of 82 to 98 percent for urinary tract infection. In Seattle, Washington, the annual risk of pyelonephritis is approximately 12-13/10 000 for women and 3-4/10 000 for men. Pyelonephritis can be stratified as ‘complicated’ or ‘uncomplicated’, depending on the presence of underlying urologic or medical conditions that predispose to kidney infection or that aggravate the severity or intransigence of such infections once they occur. Pyelonephritis is a potentially devastating complication of transplantation. Pyelonephritis can present as acute renal failure and cause graft loss. According to one series, pyelonephritis arises most often 1 year or more after transplantation (80% of episodes), and E. coli was the most common organism (80%).Acute pyelonephritis is a not an uncommon finding on renal biopsy, despite the expectation that the process is patchy. Renal biopsies are not the usual method of diagnosis, however, if neutrophils are abundant, especially if they form destructive abscesses and casts in tubules, the diagnosis should be at the top of the list. Other variants are emphysematous pyelonephritis, due to gas-producing organisms, xanthogranulomatous pyelonephritis and malakoplakia. Pyelonephritis is defined as infection and inflammation of the kidney and renal pelvis. Its diagnosis is clinical, and symptoms include back or flank pain with costovertebral angle tenderness on examination, fever (temperature higher than 38 °C), bacteriuria, and possibly nausea and vomiting. Dysuria is a less common presenting symptom for pyelonephritis. All patients with suspected pyelonephritis require a urinalysis and culture with sensitivity tests. Pyuria is almost universal in pyelonephritis, and white cell casts on urinalysis indicate upper urinary tract involvement. Infected patients can have an elevated white blood cell count, erythrocyte sedimentation rate, and C-reactive protein. Imaging is not usually required to make the diagnosis of pyelonephritis. There are surprisingly few prospective randomized trials of the treatment of pyelonephritis. For patients who require hospitalization, parenteral therapy with an aminoglycoside, a third-generation cephalosporin, or a fluoroquinolone is recommended. The first decision in the management of patients with APN is whether or not the patient requires hospitalization. Although prospective randomized trials are lacking, several retrospective studies as well as several prospective nonrandomized trials suggest that outpatient management is safe for many patients. Hospitalization should be considered for patients who cannot tolerate oral intake or who have severe pain or signs of severe sepsis.

Pyelonephritis- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pyelonephritis pipeline landscape is provided which includes the disease overview and Pyelonephritis treatment guidelines. The assessment part of the report embraces, in depth Pyelonephritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pyelonephritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pyelonephritis R&D. The therapies under development are focused on novel approaches to treat/improve Pyelonephritis.

Pyelonephritis Emerging Drugs Chapters

This segment of the Pyelonephritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pyelonephritis Emerging Drugs

WCK-5222: Wockhardt WCK 5222 (cefepime/zidebactam) is a novel ß-lactam enhancer mechanism-of-action based antibiotic designed to address the myriad of ß-lactamases that keep evolving and rendering even newer ß-lactam based antibiotics ineffective. Zidebactam is a first-in-class ß-lactam enhancer with a potent inhibition of penicillin binding protein (PBP) 2 of all the clinically relevant Gram-negative organisms including Pseudomonas aeruginosa, Acinetobacter baumannii and Enterobacterales. It is also a potent inhibitor of Ambler class A and C ß-lactamases including Klebsiella pneumoniae carbapenemases. By virtue of its universal stability to serine or metallo ß-lactamases, zidebactam synergizes with PBP 3-binding cefepime and overcomes nearly all the known enzymatic and non-enzymatic resistance mechanisms in Gram-negative pathogens. The potential clinical coverage of WCK 5222 includes metallo- ß-lactamase-expressing Enterobacterales & P. aeruginosa and carbapenem-resistant A. baumannii. This QIDP-designated antibiotic entered global Phase 3 clinicalstudies.

XNW 4107: Sinovent XNW1011 (or SN1011) is a next-generation covalent reversible BTK inhibitor that exhibits high selectivity, excellent pharmacokinetics property, robust target engagement and a safety profile that supports continued development based in part on results from a completed phase 1 study with healthy subjects conducted by SinoMab in China. Everest Medicines has entered into an exclusive licensing agreement with Suzhou Sinovent Pharmaceuticals Co., Ltd. (Sinovent) and SinoMab Bio Science Limited to develop, produce and commercialize XNW1011 (referred as SN1011 by SinoMab), a covalent reversible Bruton's tyrosine kinase (BTK) inhibitor, globally for the treatment ofrenaldiseases.

ETX2514SUL: Entasis Therapeutics ETX2514, in combination with sulbactam (the combination referred to as ETX2514SUL) in the treatment of complicated urinary tract infections (c UTI) including acute pyelonephritis (kidney infection) inadults.

Pyelonephritis: Therapeutic Assessment

This segment of the report provides insights about the different Pyelonephritis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pyelonephritis

There are approx. 8+ key companies which are developing the therapies for Pyelonephritis. The companies which have their Pyelonephritis drug candidates in the most advanced stage, i.e. Phase III, Wockhardt.

Phases

This report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Pyelonephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pyelonephritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pyelonephritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pyelonephritis drugs.

Pyelonephritis Report Insights

• Pyelonephritis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pyelonephritis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pyelonephritis drugs?
• How many Pyelonephritis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pyelonephritis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pyelonephritis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pyelonephritis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Wockhardt
• Sinovent
• Entasis Therapeutics
• Melinta Therapeutics

Key Products

• WCK-5222
• XNW 4107
• ETX2514SUL
• ORBACTIV

This product will be delivered within 2 business days.